

$GMAB has been mentioned 24 times over the past 12 months by 2 distinct FinTwit voices, with the first mention occurring on July 9, 2025. The biotech-focused voice @jacobplieth (@jacobplieth) accounts for 23 of these mentions, while @adamfeuerstein (@adamfeuerstein) contributed 1 mention. The most recent discussion occurred on February 23, 2026, with activity spanning from the initial mention through late February 2026.
Recent discussions involving $GMAB centered on competitive dynamics in oncology development. @jacobplieth referenced Genmab in the context of anti-FRα ADC (antibody-drug conjugate) development, noting how competitors like AbbVie were attempting to improve upon existing therapies in this space. The voice also discussed Genmab's involvement in HPV-positive cancer treatments and mentioned the company alongside other biotech firms in competitive analysis of pipeline programs.
@jacobplieth (Jacob Plieth) mentions $GMAB most — 23 mentions in the past 12 months.
The earliest tracked mention of $GMAB in the Surfaced archive was on Aug 7, 2025.
2 FinTwit voices have mentioned $GMAB 23 times in the past 12 months.
$GMAB is mentioned most by Biotech voices on Surfaced.
